Reviewer’s report
Title: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors
for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study
Version: 0 Date: 03 Jan 2020
Reviewer: Sunil Taneja
Reviewer's report:
Please include all comments for the authors in this box rather than uploading your report as an
attachment. Please only upload as attachments annotated versions of manuscripts, graphs, supporting
materials or other aspects of your report which cannot be included in a text format.
Please overwrite this text when adding your comments to the authors.
This is a big data collection of different Hepatitis C patients treated at multiple centres. 
Howver a few points need clarification.
The  study  population  is  variable  includes  patients  with  HCC-  Stage  of  HCC  has  not  been
mentioned,whether treated or not? what type of treatment offered? and was HCV treatment offered
before or after treatment of HCC
The second group of CKD has also been described. What was the dosing schedule of Sofosbuvir used
in various stages of CKD. what was the adverse affect profile in this group.
The Third group is HCV and HBV coinfection.- whatw as the status of hepatitis B at the start of
treatment and what antivirals were being used in Hepatistis B. Did we look at the interactions?
The fourth group is HCV and HIV coinfection. What was the status of HIV , what regimens were being
used for HIV. Was there any interactions?
The fifth group is cirrhosis- what was the dosing and duration of drugs. since ribavirin was used was
the adverse affect profile different?
The sixth group is treatment experienced- What was the treatment which they had already received and
did we look at RAVs
The seventh group is post liver transplantation patients.-What treatment regimen were used? what
immunosuppressive  medication  was  being  used?  what  were  the  interactions  with  the
immunosupprsssive drugs and what were the side effects
 
Why was the genotype I treated primarily with SOF+ Dacla when the recommended drug is SOF+ Ledi
12 week, 16 week and 24 week treatment  has been done however it has not been specified.
How many patients of Cirrhosis underwent liver biopsy?
The uniformity of the study population is not there and it becomes difficult to understand the paper.
There are lot of grammatical mistakes which need correction.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
No
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
No
Are you able to assess any statistics in the manuscript or would you recommend an
additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further
assessment in your comments to the editors.
I recommend additional statistical review
Quality of written English
Please indicate the quality of language in the manuscript:
Needs some language corrections before being published
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below.
If your reply is yes to any, please give details below.
i have no competing interests
I agree to the open peer review policy of the journal. I understand that my name will be included
on my report to the authors and, if the manuscript is accepted for publication, my named report
including any attachments I upload will be posted on the website along with the authors'
responses. I agree for my report to be made available under an Open Access Creative Commons
CC-BY license (http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments
to the editors, which will not be published.
I agree to the open peer review policy of the journal
Reviewer’s report
Title: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors
for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study
Version: 0 Date: 03 Jan 2020
Reviewer: Sunil Taneja
Reviewer's report:
Please include all comments for the authors in this box rather than uploading your report as an
attachment. Please only upload as attachments annotated versions of manuscripts, graphs, supporting
materials or other aspects of your report which cannot be included in a text format.
Please overwrite this text when adding your comments to the authors.
This is a big data collection of different Hepatitis C patients treated at multiple centres. 
Howver a few points need clarification.
The  study  population  is  variable  includes  patients  with  HCC-  Stage  of  HCC  has  not  been
mentioned,whether treated or not? what type of treatment offered? and was HCV treatment offered
before or after treatment of HCC
The second group of CKD has also been described. What was the dosing schedule of Sofosbuvir used
in various stages of CKD. what was the adverse affect profile in this group.
The Third group is HCV and HBV coinfection.- whatw as the status of hepatitis B at the start of
treatment and what antivirals were being used in Hepatistis B. Did we look at the interactions?
The fourth group is HCV and HIV coinfection. What was the status of HIV , what regimens were being
used for HIV. Was there any interactions?
The fifth group is cirrhosis- what was the dosing and duration of drugs. since ribavirin was used was
the adverse affect profile different?
The sixth group is treatment experienced- What was the treatment which they had already received and
did we look at RAVs
The seventh group is post liver transplantation patients.-What treatment regimen were used? what
immunosuppressive  medication  was  being  used?  what  were  the  interactions  with  the
immunosupprsssive drugs and what were the side effects
 
Why was the genotype I treated primarily with SOF+ Dacla when the recommended drug is SOF+ Ledi
12 week, 16 week and 24 week treatment  has been done however it has not been specified.
How many patients of Cirrhosis underwent liver biopsy?
The uniformity of the study population is not there and it becomes difficult to understand the paper.
There are lot of grammatical mistakes which need correction.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
No
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
No
Are you able to assess any statistics in the manuscript or would you recommend an
additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further
assessment in your comments to the editors.
I recommend additional statistical review
Quality of written English
Please indicate the quality of language in the manuscript:
Needs some language corrections before being published
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below.
If your reply is yes to any, please give details below.
i have no competing interests
I agree to the open peer review policy of the journal. I understand that my name will be included
on my report to the authors and, if the manuscript is accepted for publication, my named report
including any attachments I upload will be posted on the website along with the authors'
responses. I agree for my report to be made available under an Open Access Creative Commons
CC-BY license (http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments
to the editors, which will not be published.
I agree to the open peer review policy of the journal
Please review this paper.
user
Reviewer’s report
Title: Real-world effectiveness and safety of sofosbuvir and nonstructural protein 5A inhibitors
for chronic hepatitis C genotype 1, 2, 3, 4, or 6: a multicentre cohort study
Version: 0 Date: 03 Jan 2020
Reviewer: Sunil Taneja
Reviewer's report:
Please include all comments for the authors in this box rather than uploading your report as an
attachment. Please only upload as attachments annotated versions of manuscripts, graphs, supporting
materials or other aspects of your report which cannot be included in a text format.
Please overwrite this text when adding your comments to the authors.
This is a big data collection of different Hepatitis C patients treated at multiple centres. 
Howver a few points need clarification.
The  study  population  is  variable  includes  patients  with  HCC-  Stage  of  HCC  has  not  been
mentioned,whether treated or not? what type of treatment offered? and was HCV treatment offered
before or after treatment of HCC
The second group of CKD has also been described. What was the dosing schedule of Sofosbuvir used
in various stages of CKD. what was the adverse affect profile in this group.
The Third group is HCV and HBV coinfection.- whatw as the status of hepatitis B at the start of
treatment and what antivirals were being used in Hepatistis B. Did we look at the interactions?
The fourth group is HCV and HIV coinfection. What was the status of HIV , what regimens were being
used for HIV. Was there any interactions?
The fifth group is cirrhosis- what was the dosing and duration of drugs. since ribavirin was used was
the adverse affect profile different?
The sixth group is treatment experienced- What was the treatment which they had already received and
did we look at RAVs
The seventh group is post liver transplantation patients.-What treatment regimen were used? what
immunosuppressive  medication  was  being  used?  what  were  the  interactions  with  the
immunosupprsssive drugs and what were the side effects
 
Why was the genotype I treated primarily with SOF+ Dacla when the recommended drug is SOF+ Ledi
12 week, 16 week and 24 week treatment  has been done however it has not been specified.
How many patients of Cirrhosis underwent liver biopsy?
The uniformity of the study population is not there and it becomes difficult to understand the paper.
There are lot of grammatical mistakes which need correction.
Are the methods appropriate and well described?
If not, please specify what is required in your comments to the authors.
No
Does the work include the necessary controls?
If not, please specify which controls are required in your comments to the authors.
Yes
Are the conclusions drawn adequately supported by the data shown?
If not, please explain in your comments to the authors.
No
Are you able to assess any statistics in the manuscript or would you recommend an
additional statistical review?
If an additional statistical review is recommended, please specify what aspects require further
assessment in your comments to the editors.
I recommend additional statistical review
Quality of written English
Please indicate the quality of language in the manuscript:
Needs some language corrections before being published
Declaration of competing interests
Please complete a declaration of competing interests, considering the following questions:
1. Have you in the past five years received reimbursements, fees, funding, or salary from an
organisation that may in any way gain or lose financially from the publication of this
manuscript, either now or in the future?
2. Do you hold any stocks or shares in an organisation that may in any way gain or lose
financially from the publication of this manuscript, either now or in the future?
3. Do you hold or are you currently applying for any patents relating to the content of the
manuscript?
4. Have you received reimbursements, fees, funding, or salary from an organization that holds
or has applied for patents relating to the content of the manuscript?
5. Do you have any other financial competing interests?
6. Do you have any non-financial competing interests in relation to this paper?
If you can answer no to all of the above, write 'I declare that I have no competing interests' below.
If your reply is yes to any, please give details below.
i have no competing interests
I agree to the open peer review policy of the journal. I understand that my name will be included
on my report to the authors and, if the manuscript is accepted for publication, my named report
including any attachments I upload will be posted on the website along with the authors'
responses. I agree for my report to be made available under an Open Access Creative Commons
CC-BY license (http://creativecommons.org/licenses/by/4.0/ ). I understand that any comments
which I do not wish to be included in my named report can be included as confidential comments
to the editors, which will not be published.
I agree to the open peer review policy of the journal
assistant